🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationHas anyone dealt with peptide oxidation and deamidation?

Has anyone dealt with peptide oxidation and deamidation?

ZaraB_AL Sat, Jan 10, 2026 at 12:20 PM 28 replies 1,096 viewsPage 1 of 6
ZaraB_AL
Member
456
1,678
Jan 2025
Alabama
Jan 10, 2026 at 12:20 PM#1

Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within weeks of each other.

The bit I cannot resolve on my own is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.

Numbers rather than impressions, if you have them.

3 23JessicaH_TX, KevinCompounds, TirzTom
Reply Quote Save Share Report
mike_nyc
VIP Member
5,678
21,345
Nov 2023
New York
Online
Jan 10, 2026 at 12:44 PM#2

Short answer first, then the reasoning. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

2 22stefan_berlin, Dr.EM_Chicago
Reply Quote Save Share Report
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Jan 10, 2026 at 1:08 PM#3
mike_nyc said:
They are two different exemptions from the same federal requirements and they buy different things.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

Last edited: Jan 10, 2026 at 2:08 PM
1 21COA_Karl
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Jan 10, 2026 at 1:32 PM#4
ZaraB_AL said:
Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…

Same position here, arrived at the long way round. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

50 20marco_milano, pam_columbus, nick_SD_fit and 47 others
Reply Quote Save Share Report
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
Jan 10, 2026 at 3:45 PM#5

Clinical perspective, offered as context rather than as advice.

Compounding pharmacy response time test for compounded supply: I email customer service at odd hours to test responsiveness. A pharmacy that can't answer questions promptly is a red flag.

My current pharmacy: average response time 2 hours. They answered my questions about storage conditions thoroughly and professionally.

Communication quality is a proxy for operational quality. A pharmacy that communicates well is likely manufacturing well too.

Last edited: Jan 10, 2026 at 6:45 PM
49 19WendyG_ATL, SaraMom3, Dr.MetabolicMD and 46 others
Reply Quote Save Share Report
1236

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register